Teva's 2024 Healthy Future Report Highlights Sustainability Progress, Including Surpassed Targets Linked to Financial Strategy

TEL AVIV, IL / ACCESS Newswire / May 13, 2025 / Teva Pharmaceutical

• The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule

Teva launched two new programs to help people around the world access the medicines they need, for a total of nine programs, surpassing its target of eight programs by 2025

More than 99% of Teva employees were trained on compliance and ethics, and more than 40% of its significant suppliers were evaluated for sustainability performance

Teva received improved scores for sustainability progress from rating organizations, including its highest score to date from EcoVadis

Teva's generic medicines contributed to $39.7 billion in savings for healthcare systems across 22 countries

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) published its 2024 Healthy Future Report, sharing actions to advance its sustainability strategy. Teva achieved or surpassed many of its targets, some ahead of schedule. This includes targets tied to sustainable finance instruments, which directly connect its progress in increasing access to medicines and minimizing environmental impact to the Company's financial success. Healthy Future is focused on topics most relevant to Teva's business, supporting the Company in advancing its purpose-we are all in for better health-and enhancing its resilience.

Healthy People
Teva launched two new access to medicines programs-one in El Salvador and a global emergency stockpile-for a total of nine, surpassing its target of eight programs by 2025. Through these nine programs, Teva donated ~18 million doses of medicine, worth $23 million, and provided 2.2 million doses at low cost, reaching 187,000 patients. Five programs also focus on health systems strengthening and capacity building and benefitted ~56,000 individuals.

Healthy Planet
Teva achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas (GHG) emissions from 2019 levels, surpassing its target of 25% by 2025 ahead of schedule. Additionally, 73% of applicable Teva sites achieved safe discharge levels of antibiotics, minimizing environmental pollution and supporting public health. Through a new antimicrobial resistance capacity-building pilot program in Germany, the Company educated more than 65,000 healthcare professionals, leading to approximately 389,000 patient interactions about appropriate use of antibiotics.